Google
JNJ Stock Analysis — JOHNSON & JOHNSON (Healthcare >> Drug Manufacturers - General)
JNJ FAQ
What is JNJ's P/E ratio?
JOHNSON & JOHNSON (JNJ) currently trades at a P/E ratio of 29.31.
What is JNJ's ROE?
JOHNSON & JOHNSON reports a Return on Equity (ROE) of 24.76%.
What is JNJ's dividend yield?
JOHNSON & JOHNSON offers a dividend yield of 1.97%.
What is JNJ's Quality Score?
Our AI rates JNJ's overall financial quality at 85 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy JNJ?
Our AI Timing Score for JNJ is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does JNJ belong to?
JOHNSON & JOHNSON is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange
JNJ AI Analysis Summary
Our AI summary for JNJ: JOHNSON & JOHNSON (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 29.31, ROE of 24.76%, a dividend yield of 1.97%. Its financial Quality Score stands at 85/100 — fundamentals stronger than most of the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 256.35
Price
0.53
(0.21%)
Day Change
|
|
|---|
JNJ, the overall quality is very good ( Quality = 85) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROE is decreasing significantly
ROA is too relatively low compare to ROE
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Quality Factors |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
1050
|
| Magic Formula Rank by ROE |
1050
|
| Magic Formula Rank by ROIC |
1342
|
| Price | 256.35 |
| PBV / Sector |
7.26 / 2.68
|
| Earning Per Share | 8.75 |
| PE / Sector |
29.31 / 27.65
|
| PEG or PE/Growth / Sector |
N/A / 0.28
|
| Average 1M Daily Value |
1,761.97 M
GREAT
|
| Average 1W Daily Value |
1,751.55 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
58% |
| Ability to Make Profit |
|
75% |
| Return to Investors |
|
12% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:04 |
| Symbol | JNJ |
| Name | JOHNSON & JOHNSON |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 2,409.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 616,500.23 / 256,404.20 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
Phone: 732 524 0400
Website: https://www.jnj.com
Employees: 138,200
Description: Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
